KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Prepaid Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Prepaid Assets for 13 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 50.83% to $10.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.4 million, a 50.83% increase, with the full-year FY2025 number at $10.4 million, up 50.83% from a year prior.
  • Prepaid Assets was $10.4 million for Q4 2025 at Xenon Pharmaceuticals, down from $17.1 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $17.1 million in Q3 2025 to a low of $2.9 million in Q2 2023.
  • A 5-year average of $6.3 million and a median of $5.2 million in 2022 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: tumbled 58.53% in 2023, then soared 264.0% in 2025.
  • Xenon Pharmaceuticals' Prepaid Assets stood at $4.5 million in 2021, then surged by 61.24% to $7.2 million in 2022, then decreased by 16.87% to $6.0 million in 2023, then rose by 14.72% to $6.9 million in 2024, then skyrocketed by 50.83% to $10.4 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Prepaid Assets are $10.4 million (Q4 2025), $17.1 million (Q3 2025), and $11.6 million (Q2 2025).